Rangeley Capital LLC Invests $1.67 Million in Theravance Biopharma, Inc. $TBPH

Rangeley Capital LLC purchased a new stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 103,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,672,000. Theravance Biopharma accounts for about 1.5% of Rangeley Capital LLC’s investment portfolio, making the stock its 22nd largest position.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. AQR Capital Management LLC acquired a new position in shares of Theravance Biopharma during the first quarter valued at about $101,000. Jane Street Group LLC increased its stake in Theravance Biopharma by 169.2% during the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company’s stock valued at $1,258,000 after acquiring an additional 88,540 shares during the period. Creative Planning acquired a new position in Theravance Biopharma in the 2nd quarter valued at approximately $139,000. American Century Companies Inc. lifted its position in shares of Theravance Biopharma by 6.8% in the 2nd quarter. American Century Companies Inc. now owns 91,501 shares of the biopharmaceutical company’s stock worth $1,009,000 after acquiring an additional 5,794 shares during the period. Finally, Invesco Ltd. lifted its position in shares of Theravance Biopharma by 12.4% in the 2nd quarter. Invesco Ltd. now owns 25,324 shares of the biopharmaceutical company’s stock worth $279,000 after acquiring an additional 2,789 shares during the period. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Theravance Biopharma

In related news, major shareholder Eli Samaha sold 37,799 shares of Theravance Biopharma stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $17.00, for a total value of $642,583.00. Following the completion of the transaction, the insider directly owned 9,174,453 shares of the company’s stock, valued at $155,965,701. The trade was a 0.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Rhonda Farnum sold 13,314 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $16.39, for a total transaction of $218,216.46. Following the transaction, the senior vice president owned 232,457 shares in the company, valued at approximately $3,809,970.23. This trade represents a 5.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 350,011 shares of company stock worth $6,008,309 in the last 90 days. Company insiders own 7.65% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TBPH. Zacks Research lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, June 8th. B. Riley Financial upped their target price on Theravance Biopharma from $14.00 to $17.00 and gave the company a “neutral” rating in a research note on Tuesday, April 7th. JonesTrading cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Monday, June 29th. BTIG Research downgraded shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a research note on Monday, June 29th. Finally, Weiss Ratings lowered shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 27th. Eight analysts have rated the stock with a Hold rating, According to data from MarketBeat, Theravance Biopharma presently has an average rating of “Hold” and a consensus target price of $19.40.

Theravance Biopharma Price Performance

NASDAQ TBPH opened at $16.86 on Monday. The firm has a market cap of $869.18 million, a PE ratio of 7.66 and a beta of 0.17. Theravance Biopharma, Inc. has a one year low of $10.82 and a one year high of $21.03. The stock’s 50 day simple moving average is $16.66 and its 200 day simple moving average is $17.10.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. The business had revenue of $17.70 million for the quarter. As a group, equities analysts expect that Theravance Biopharma, Inc. will post 1.54 earnings per share for the current year.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.